Reproductive Health News

Procedural-induced abortion may be slightly safer than pharmaceutical-induced abortion, although both are safe and effective, according to researchers.

The FDA finalized changes to its dispensing requirements for mifepristone to allow certified pharmacies to provide the abortifacient to patients, according to updated postmarket drug safety information.

Restrictions on reproductive care access were associated with higher state-level rates of suicide among reproductive-aged women, according to a study published in JAMA Psychiatry.

The rate of cocaine use during pregnancy increased in a Northern California health system compared with population-level increases in the United States from 2011 to 2019, according to a study in JAMA Network Open.

This year, women’s health care providers have faced challenges that developed throughout the year, from the lingering COVID-19 pandemic to a changing legal landscape.

Gestational diabetes is associated with a high risk for long-term CV outcomes, according to a presentation at The Pregnancy Meeting this year.

Children exposed to benzodiazepines and/or nonbenzodiazepines, also known as z-hypnotics, prenatally may not have increased risk for ADHD, according to data published in JAMA Network Open.

The FDA has updated the consumer information leaflet for levonorgestrel 1.5 mg, or Plan B One-Step, to specify that this medication is not an abortifacient and will not affect an existing pregnancy.

Pregnant people who self-reported cannabis use perceived benefits of cannabis legalization, but also reported worries about the implications for the involvement of Child Protective Services, according to data published in JAMA Network Open.

Among Healio Women’s Health & OB/GYN content, abortion-related articles were some of the most read content this year.